Premium
Increased expression of lysosome membrane protein 2 in glomeruli of patients with idiopathic membranous nephropathy
Author(s) -
Rood Ilse M.,
Merchant Michael L.,
Wilkey Daniel W.,
Zhang Terry,
Zabrouskov Vlad,
der Vlag Johan,
Dijkman Henry B.,
Willemsen Brigith K.,
Wetzels Jack F.,
Klein Jon B.,
Deegens Jeroen K.
Publication year - 2015
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201500127
Subject(s) - microvesicles , glomerular basement membrane , urinary system , proteomics , proteome , membranous nephropathy , nephropathy , medicine , pathology , focal segmental glomerulosclerosis , biomarker , glomerulonephritis , minimal change disease , kidney , endocrinology , biology , bioinformatics , biochemistry , diabetes mellitus , microrna , gene
Urinary microvesicles constitute a rich source of membrane‐bound and intracellular proteins that may provide important clues of pathophysiological mechanisms in renal disease. In the current study, we analyzed and compared the proteome of urinary microvesicles from patients with idiopathic membranous nephropathy (iMN), idiopathic focal segmental glomerulosclerosis (iFSGS), and normal controls using an approach that combined both proteomics and pathology analysis. Lysosome membrane protein‐2 (LIMP‐2) was increased greater than twofold in urinary microvesicles obtained from patients with iMN compared to microvesicles of patients with iFSGS and normal controls. Immunofluorescence analysis of renal biopsies confirmed our proteomics findings that LIMP‐2 was upregulated in glomeruli from patients with iMN but not in glomeruli of diseased patients (iFSGS, minimal change nephropathy, IgA nephropathy, membranoproliferative glomerulonephritis) and normal controls. Confocal laser microscopy showed co‐localization of LIMP‐2 with IgG along the glomerular basement membrane. Serum antibodies against LIMP‐2 could not be detected. In conclusion, our data show the value of urinary microvesicles in biomarker discovery and provide evidence for de novo expression of LIMP‐2 in glomeruli of patients with iMN.